Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
4.39
Dollar change
-0.29
Percentage change
-6.20
%
Index- P/E- EPS (ttm)-2.93 Insider Own32.88% Shs Outstand82.29M Perf Week-12.20%
Market Cap362.31M Forward P/E- EPS next Y-1.78 Insider Trans0.00% Shs Float55.39M Perf Month12.56%
Income-239.38M PEG- EPS next Q-0.55 Inst Own56.32% Short Float1.79% Perf Quarter112.08%
Sales69.56M P/S5.21 EPS this Y27.63% Inst Trans5.46% Short Ratio1.32 Perf Half Y441.98%
Book/sh-1.80 P/B- EPS next Y16.12% ROA-54.16% Short Interest0.99M Perf Year117.33%
Cash/sh3.38 P/C1.30 EPS next 5Y15.80% ROE-705.53% 52W Range0.36 - 6.04 Perf YTD164.46%
Dividend Est.- P/FCF- EPS past 5Y84.52% ROI- 52W High-27.32% Beta1.72
Dividend TTM- Quick Ratio4.73 Sales past 5Y91.46% Gross Margin95.21% 52W Low1119.76% ATR (14)0.46
Dividend Ex-Date- Current Ratio4.97 EPS Y/Y TTM-46.47% Oper. Margin-240.28% RSI (14)47.50 Volatility9.01% 10.15%
Employees162 Debt/Eq- Sales Y/Y TTM-66.86% Profit Margin-344.15% Recom1.50 Target Price10.20
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-244.89% Payout- Rel Volume0.45 Prev Close4.68
Sales Surprise9.64% EPS Surprise-105.14% Sales Q/Q-75.94% EarningsMar 13 BMO Avg Volume755.13K Price4.39
SMA20-2.30% SMA50-2.21% SMA200110.34% Trades Volume336,990 Change-6.20%
Date Action Analyst Rating Change Price Target Change
Mar-28-24Initiated Guggenheim Buy $11
Aug-10-23Upgrade JP Morgan Underweight → Neutral
Apr-24-23Downgrade BofA Securities Neutral → Underperform $7 → $2
Dec-06-22Initiated CapitalOne Overweight $12
Nov-09-22Downgrade BofA Securities Buy → Neutral $14 → $7
Sep-21-22Initiated JP Morgan Overweight $5
Sep-09-22Downgrade Morgan Stanley Overweight → Equal-Weight $17 → $11
Nov-09-21Initiated Wolfe Research Outperform $44
Aug-17-21Resumed Jefferies Buy $40
Aug-09-21Initiated RBC Capital Mkts Outperform $33
Apr-04-24 07:00AM
Apr-03-24 07:00AM
Apr-01-24 04:05PM
Mar-15-24 12:30PM
Mar-14-24 05:16AM
08:51AM Loading…
Mar-13-24 08:51AM
08:20AM
07:00AM
Mar-06-24 07:15AM
07:00AM
Mar-05-24 05:45PM
Feb-27-24 07:00AM
Feb-20-24 10:00AM
Feb-16-24 03:57AM
Feb-15-24 11:57AM
01:15PM Loading…
Feb-08-24 01:15PM
Jan-19-24 01:05PM
09:40AM
Jan-04-24 10:05AM
07:15AM
07:00AM
Dec-12-23 05:15AM
Nov-20-23 02:40AM
Nov-15-23 03:00AM
Nov-08-23 01:26PM
01:03AM
Nov-07-23 08:15AM
07:15AM
07:00AM
Nov-06-23 07:00AM
05:50PM Loading…
Nov-02-23 05:50PM
10:10AM
Nov-01-23 10:01AM
Oct-31-23 10:01AM
Oct-24-23 07:00AM
Oct-04-23 04:00AM
Sep-05-23 07:00AM
Aug-30-23 07:33PM
Aug-14-23 10:51AM
Aug-11-23 10:53AM
Aug-10-23 10:31AM
Aug-09-23 12:09PM
Aug-08-23 11:01PM
10:48AM
08:15AM
07:00AM
Aug-07-23 05:25PM
Aug-04-23 08:40AM
08:12AM
Aug-03-23 11:48AM
11:45AM
08:02AM
Aug-02-23 12:45PM
12:42PM
Aug-01-23 10:45AM
07:22AM
07:00AM
Jul-28-23 08:02AM
Jul-26-23 08:52AM
Jul-24-23 01:20PM
11:12AM
07:21AM
Jul-21-23 01:22PM
07:44AM
Jul-20-23 04:05PM
Jul-19-23 09:59AM
Jul-18-23 11:04AM
Jul-17-23 10:59AM
10:06AM
Jul-14-23 10:56AM
09:55AM
08:03AM
Jul-13-23 09:35AM
07:08AM
Jul-12-23 10:27AM
Jul-11-23 12:50PM
10:24AM
07:17AM
07:00AM
Jun-15-23 07:15AM
Jun-09-23 07:15AM
Jun-01-23 07:15AM
May-11-23 12:33PM
06:17AM
May-10-23 07:15AM
06:09AM
May-09-23 08:15AM
07:00AM
May-02-23 10:01AM
07:15AM
May-01-23 10:01AM
Apr-17-23 02:53PM
Mar-22-23 03:44AM
Mar-15-23 03:11PM
Mar-08-23 11:54AM
Mar-07-23 09:35AM
Mar-03-23 11:18AM
Mar-01-23 07:15AM
Feb-28-23 08:35AM
07:00AM
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.